» Articles » PMID: 19432671

Detection of M2 Macrophages and Colony-stimulating Factor 1 Expression in Serous and Mucinous Ovarian Epithelial Tumors

Overview
Journal Pathol Int
Specialty Pathology
Date 2009 May 13
PMID 19432671
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAM) are known to possess the immunosuppressive M2 macrophage phenotype. They contribute to tumor growth, invasion, and metastasis by producing various mediators. Macrophages, especially M2 polarized macrophages, preferentially express CD163 and CD204, but few studies have investigated macrophage phenotypes in human ovarian tumors. The purpose of the present study was therefore to present results on macrophage differentiation in human ovarian serous and mucinous epithelial tumors. The method focused on immunostaining of paraffin-embedded tumor samples. Almost all macrophages infiltrating tumor tissues expressed CD163 and CD204, indicating the phenotypic shift toward M2 macrophage. The numbers of CD68-positive macrophages as well as of CD163- and CD204-positive macrophages in borderline and malignant tumors were significantly higher than in benign tumors. They correlated well with histological gradient of malignancy. Macrophage colony-stimulating factor (also known as colony-stimulating factor; CSF-1), which is one of the cytokines considered to induce TAM to polarize toward an M2 phenotype, was then evaluated. CSF-1 expression in malignant tumor cells was significantly higher than that in benign tumor cells and correlated with histological malignancy. These results suggest that CSF-1 derived from tumor tissues induces macrophages to shift toward the M2 phenotype, which is considered to promote tumor growth.

Citing Articles

Adipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression.

Liermann-Wooldrik K, Kosmacek E, Oberley-Deegan R Int J Mol Sci. 2024; 25(22).

PMID: 39596205 PMC: 11594286. DOI: 10.3390/ijms252212137.


Ubiquitin-related gene markers predict immunotherapy response and prognosis in patients with epithelial ovarian carcinoma.

Luo D, Li X, Wei L, Yu Y, Hazaisihan Y, Tao L Sci Rep. 2024; 14(1):25239.

PMID: 39448713 PMC: 11502900. DOI: 10.1038/s41598-024-76945-2.


YKL40/Integrin β4 Axis Induced by the Interaction between Cancer Cells and Tumor-Associated Macrophages Is Involved in the Progression of High-Grade Serous Ovarian Carcinoma.

Yamanaka K, Koma Y, Urakami S, Takahashi R, Nagamata S, Omori M Int J Mol Sci. 2024; 25(19).

PMID: 39408927 PMC: 11477481. DOI: 10.3390/ijms251910598.


Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.

Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J Nat Commun. 2024; 15(1):5932.

PMID: 39013886 PMC: 11252308. DOI: 10.1038/s41467-024-47000-5.


LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer.

Liu J, Yan C, Xu S Cell Death Dis. 2024; 15(5):313.

PMID: 38702326 PMC: 11068771. DOI: 10.1038/s41419-024-06704-8.